{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:11Z","timestamp":1786951451142,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01318-4","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:03:39Z","timestamp":1784711019000},"page":"1243-1257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Memantine Augmentation in Obsessive-Compulsive Disorder: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2651-9754","authenticated-orcid":false,"given":"Stanley","family":"Lyndon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53\u201363. https:\/\/doi.org\/10.1038\/mp.2008.94.","journal-title":"Mol Psychiatry"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:400\u201312. https:\/\/doi.org\/10.1016\/j.pnpbp.2005.11.028.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1318_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152352","volume":"120","author":"PJ van Roessel","year":"2023","unstructured":"van Roessel PJ, Grassi G, Aboujaoude EN, Mench\u00f3n JM, Van Ameringen M, Rodr\u00edguez CI. Treatment-resistant OCD: pharmacotherapies in adults. Compr Psychiatry. 2023;120:152352. https:\/\/doi.org\/10.1016\/j.comppsych.2022.152352.","journal-title":"Compr Psychiatry"},{"key":"1318_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv047","volume":"18","author":"M Dold","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18:pyv047. https:\/\/doi.org\/10.1093\/ijnp\/pyv047.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1318_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2893","volume":"39","author":"D Conti","year":"2024","unstructured":"Conti D, Girone N, Boscacci M, Casati L, Cassina N, Cerolini L, et al. The use of antipsychotics in obsessive compulsive disorder. Hum Psychopharmacol. 2024;39:e2893. https:\/\/doi.org\/10.1002\/hup.2893.","journal-title":"Hum Psychopharmacol"},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/1570159X15666170320104237","volume":"15","author":"Z Marinova","year":"2017","unstructured":"Marinova Z, Chuang D-M, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15:977\u201395. https:\/\/doi.org\/10.2174\/1570159X15666170320104237.","journal-title":"Curr Neuropharmacol"},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1038\/s41380-020-01007-8","volume":"26","author":"E Shephard","year":"2021","unstructured":"Shephard E, Stern ER, van den Heuvel OA, Costa DLC, Batistuzzo MC, Godoy PBG, et al. Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder. Mol Psychiatry. 2021;26:4583\u2013604. https:\/\/doi.org\/10.1038\/s41380-020-01007-8.","journal-title":"Mol Psychiatry"},{"key":"1318_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0102-3","volume":"5","author":"DJ Stein","year":"2019","unstructured":"Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5:52. https:\/\/doi.org\/10.1038\/s41572-019-0102-3.","journal-title":"Nat Rev Dis Primers"},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0972-6748.132930","volume":"22","author":"AK Bakhla","year":"2013","unstructured":"Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J. 2013;22:149\u201352. https:\/\/doi.org\/10.4103\/0972-6748.132930.","journal-title":"Ind Psychiatry J"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.64719\/pb.4096","volume":"42","author":"JD Feusner","year":"2009","unstructured":"Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42:81\u201393.","journal-title":"Psychopharmacol Bull"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1176\/appi.ajp.2020.20111601","volume":"178","author":"WK Goodman","year":"2021","unstructured":"Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. Am J Psychiatry. 2021;178:17\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20111601.","journal-title":"Am J Psychiatry"},{"key":"1318_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"C Pittenger","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132:314\u201332. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.09.006.","journal-title":"Pharmacol Ther"},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0043-118665","volume":"51","author":"P Vl\u010dek","year":"2018","unstructured":"Vl\u010dek P, Pol\u00e1k J, Brunovsk\u00fd M, Hor\u00e1\u010dek J. Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications. Pharmacopsychiatr. 2018;51:229\u201342. https:\/\/doi.org\/10.1055\/s-0043-118665.","journal-title":"Pharmacopsychiatr"},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1691\/ph.2023.2584","volume":"78","author":"E Kose","year":"2023","unstructured":"Kose E, Yamamoto T, Tate N, Ando A, Enomoto H, Yasuno N. Adverse drug event profile associated with anti-dementia drugs: analysis of a spontaneous reporting database. Pharmazie. 2023;78:42\u20136. https:\/\/doi.org\/10.1691\/ph.2023.2584.","journal-title":"Pharmazie"},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47:175\u201380. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.09.015.","journal-title":"J Psychiatr Res"},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"M Haghighi","year":"2013","unstructured":"Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology. 2013;228:633\u201340. https:\/\/doi.org\/10.1007\/s00213-013-3067-z.","journal-title":"Psychopharmacology"},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0043-120268","volume":"51","author":"A Modarresi","year":"2018","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatr. 2018;51:263\u20139. https:\/\/doi.org\/10.1055\/s-0043-120268.","journal-title":"Pharmacopsychiatr"},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.07.008","volume":"104","author":"V Farnia","year":"2018","unstructured":"Farnia V, Gharehbaghi H, Alikhani M, Almasi A, Golshani S, Tatari F, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatr Res. 2018;104:137\u201343. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.07.008.","journal-title":"J Psychiatr Res"},{"key":"1318_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03642-z","volume":"22","author":"S Askari","year":"2022","unstructured":"Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022;22:34. https:\/\/doi.org\/10.1186\/s12888-021-03642-z.","journal-title":"BMC Psychiatry"},{"key":"1318_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-06856-7","volume":"25","author":"H Mirzazadeh","year":"2025","unstructured":"Mirzazadeh H, Ghaeminia Y, Mohamad Niaei A, Kamran M, Razeghian Jahromi L, Moshfeghinia R. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial. BMC Psychiatry. 2025;25:561. https:\/\/doi.org\/10.1186\/s12888-025-06856-7.","journal-title":"BMC Psychiatry"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JAD-180237","volume":"64","author":"T Kishi","year":"2018","unstructured":"Kishi T, Matsuda Y, Iwata N. Combination therapy of serotonin reuptake inhibitors and memantine for obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. J Alzheimers Dis. 2018;64:43\u20138. https:\/\/doi.org\/10.3233\/JAD-180237.","journal-title":"J Alzheimers Dis"},{"key":"1318_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112602","volume":"282","author":"A Modarresi","year":"2019","unstructured":"Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602. https:\/\/doi.org\/10.1016\/j.psychres.2019.112602.","journal-title":"Psychiatry Res"},{"key":"1318_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The Prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1318_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164.","journal-title":"Res Synth Methods"},{"key":"1318_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010247","volume":"6","author":"J IntHout","year":"2016","unstructured":"IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6:e010247. https:\/\/doi.org\/10.1136\/bmjopen-2015-010247.","journal-title":"BMJ Open"},{"key":"1318_CR27","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"BMJ"},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01318-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:37Z","timestamp":1786948117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01318-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01318-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data analysed in this study are available in the published studies included in the systematic review and referenced within the manuscript.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statistical code is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stanley Lyndon: Conceptualization, Methodology, Validation, Formal Analysis, Data Curation, Writing \u2013 Original Draft, Writing \u2013 Review & Editing, Visualization; Donald R. McNally: Validation, Data Curation, Writing \u2013 Review & Editing. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}